This inventor holds 2 USPTO granted patents. Top assignees: Chu Nantes, National Institute of Health and Medical Research, The University of Nantes. Active years: 2013-2015.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Nantes Cedex 1, FR (2013)
- Nantes Cedex, FR (2015)
Company Filing History:
2 out of 18 
2 out of 1,853 
2 out of 156 
Years Active: 2013-2015
Title: Agnes Moreau-Aubry: Innovator in Melanoma Research
Introduction
Agnes Moreau-Aubry is a prominent inventor based in Nantes, France. She has made significant contributions to the field of melanoma research, particularly through her innovative patents. With a total of two patents to her name, her work focuses on novel melanoma antigen peptides and their applications in treatment.
Latest Patents
Agnes Moreau-Aubry's latest patents include "Melanoma antigen peptide and uses thereof." This invention relates to novel melanoma antigen peptides and specific T lymphocytes directed to these peptides, aimed at treating melanoma. Her research has the potential to advance therapeutic options for patients suffering from this aggressive form of skin cancer.
Career Highlights
Throughout her career, Agnes has worked with esteemed institutions such as the Institut National de la Santé et de la Recherche Médicale and the Université de Nantes. Her dedication to research and innovation has positioned her as a key figure in the scientific community, particularly in the realm of cancer research.
Collaborations
Agnes has collaborated with notable colleagues, including Nathalie Labarriere and Yann Godet. These partnerships have further enriched her research endeavors and contributed to the advancement of melanoma treatment strategies.
Conclusion
Agnes Moreau-Aubry's work exemplifies the impact of innovative research in the medical field. Her contributions to melanoma research through her patents highlight the importance of continued exploration and development in cancer therapies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile